Eurofarma completes takeover of Takeda assets for Latin America

By:
 
Feb. 12, 2021 - PRLog -- Eurofarma, with its own operation in 20 countries across Latin America, announces the closing of the Takeda asset purchase in a long process lasting almost 10 months and which also included the participation of Hypera Pharma, which maintains the Takeda assets in the Brazilian market.

The largest Eurofarma acquisition in terms of value, the brand includes 12 drugs in all, including own and licensed, over-the-counter and prescription, which total USD 38 million in sales. Mexico accounts for more than 90% of revenue.

The decision is in line with the organization's strategic plan to become a strong regional competitor and with the goal of international revenues representing 30% of the company's total by 2022. The acquisition also contributes to expanding the company's exclusive portfolio, since some acquired products are protected by patent.

"In line with our strategy of also growing through acquisitions, this is a milestone in our history because it empowers us to enter Mexico, the second largest market in Latin America, in a relevant manner. We are incorporating brands recognized by the medical profession and we will add these assets to the Keflex® product, recently acquired from Lilly in Mexico. Eurofarma also has a broad pipeline and some processes that have already been registered. Thus, we will have a robust platform in the country to meet our ambitions and receive investments," says Maria Del Pilar Muñoz, vice president of Sustainability and New Business.

With a lesser representation, the acquisition includes assets in Argentina (Budeson, Nene-dent), Ecuador (Abothyl), Central America and Peru (Abothyl), with emphasis on Neosaldina® in Colombia. Mexico (Edarbi, Incresina, Venalot, Arbistin, Turazive, Luivac, Nene-dent, Cyntelle O3, Abothyl, Sanostol).

About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people's quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.

Contact
Glauce Martins
***@gaspar.com.br
End
Email:***@gaspar.com.br
Posted By:***@gaspar.com.br Email Verified
Tags:Eurofarma
Industry:Business
Location:México State - Mexico
Subject:Mergers
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
G&A RP PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share